Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
54 Results for "
VCAP
" in MedChemExpress (MCE) Product Catalog:
Products (54)
54 Results for "VCAP" in MCE Product Catalog:
Cat. No.: HY-185786
CAS No.: 3105154-92-2
Research Areas:
CBP/p300-IN-25 is a CBP/p300 heterobifunctional conditional inhibitor. CBP/p300-IN-25 mediates conditional CBP/p300 inhibition through simultaneous binding to CBP/p300 and AR. CBP/p300-IN-25 is applicable to the research of prostate cancer .
Cat. No.: HY-175937
CAS No.: 2682256-03-5
Research Areas:
AR ligand-46 is an androgen receptor (AR) ligand that can be used in studies related to PROTAC synthesis, such as serving as a target protein ligand for A031 (HY-148777) .
Cat. No.: HY-112083R
CAS No.: 2377576-35-5
Target:
Research Areas:
BAY-3827 (Standard) is the analytical standard of BAY-3827 (HY-112083). This product is intended for research and analytical applications. BAY-3827, a chemical probe, is a potent and selective AMPK inhibitor with IC50 values of 1.4 nM at low (10 μM ATP concentration) and 15 nM at high (2 mM ATP concentration). BAY-3827 shows over 500-fold selectivity for most of the 331 Kinases. BAY-3827 prevents phosphorylation of acetyl-CoA carboxylase 1 and shows strongest anti-proliferative activity in androgen-dependent prostate cancer cell lines .
Cat. No.: HY-150812
CAS No.: 2308497-42-7
Target:
Research Areas:
VHL Ligand 23 is a VHL ligand with a IC50 value of 26.8 nM. VHL Ligand 23 can be used in the research of prostate cancer .
Cat. No.: HY-181727
Research Areas:
AR/AR-V7 degrader-1 is an orally active AR and AR-V7 degrader. AR/AR-V7 degrader-1 disrupts the interaction between AR/AR-V7 and HSP90, leading to their ubiquitination and degradation in castration-resistant prostate cancer cells. AR/AR-V7 degrader-1 regulates the expression of cell cycle-related proteins in prostate cancer cells (downregulates CDK4, CDK6, Cyclin D1, Cyclin E1; upregulates P21) and induces G0/G1 phase arrest. AR/AR-V7 degrader-1 inhibits the proliferation and migration of prostate cancer cells. AR/AR-V7 degrader-1 suppresses the growth of castration-resistant prostate cancer tumors in nude mice and induces the degradation of AR and AR-V7 in tumor tissues. AR/AR-V7 degrader-1 is applicable to the research of castration-resistant prostate cancer .
Cat. No.: HY-184005
IHMT-BMX-068 is a BMX PROTAC degrader with a DC50 of 0.007 μM. IHMT-BMX-068 promotes ubiquitination and degradation of BMX. IHMT-BMX-068 increases the levels of cleaved PARP and cleaved Caspase-3, and induces Apoptosis. IHMT-BMX-068 exerts anti-cancer effects against prostate cancer. IHMT-BMX-068 can be used for the research of prostate cancer .
Cat. No.: HY-182468
CAS No.: 3056105-63-3
Synonyms: OP-3136
Target:
Research Areas:
Omvitrastat (OP-3136) is an orally active, highly selective inhibitor of KAT6A and KAT6B. Omvitrastat inhibits the proliferation of prostate cancer, ovarian cancer and non-small cell lung cancer cells that express or overexpress KAT6A. Omvitrastat reduces the proliferative capacity of cancer cells and suppresses cell growth in ER + breast cancer cell models with KAT6 overexpression. Omvitrastat induces tumor regression and inhibits tumor growth in an ovarian cancer xenograft model in immunodeficient mice. Omvitrastat inhibits tumor growth in a non-small cell lung cancer xenograft model in immunodeficient mice. Omvitrastat can be used in research related to HR +/HER 2- breast cancer, prostate cancer, ovarian cancer and non-small cell lung cancer (NSCLC) .
Cat. No.: HY-171808
CAS No.: 2798907-16-9
Target:
Research Areas:
ITRI-90 is an orally effective androgen receptor (AR) PROTAC degrader. ITRI-90 effectively degrades full-length AR (AR-FL) and its splice variant AR-V7 proteins via the ubiquitin-proteasome system, thereby inhibiting AR transcriptional activity and the expression of its target genes, and further inducing tumor cell apoptosis. ITRI-90 can be used in research related to castration-resistant prostate cancer and Enzalutamide (HY-70002)-resistant prostate cancer .
Cat. No.: HY-188148
CAS No.: 158437-84-4
Target:
Research Areas:
ETS transcription factor-IN-1 is an inhibitor of ETS transcription factor. ETS transcription factor-IN-1 blocks the binding of the ETS DNA-binding domain to consensus ETS DNA-binding sites, thereby inhibiting the function of ETS transcription factors such as ETV6, ERG, and FLI1. ETS transcription factor-IN-1 inhibits angiogenesis and tumor cell proliferation in cancer cell lines with ETS abnormalities. ETS transcription factor-IN-1 can be used in research related to prostate cancer and breast cancer .
Cat. No.: HY-184124
Research Areas:
JYZ3032 is an orally active super inhibitor of androgen receptor (AR) and p300/CBP. JYZ3032 redirects the catalytic activity of p300 and locks the complex in a transcriptionally inactive state, thereby inhibiting AR-driven transcription and proliferation. JYZ3032 induces deep and durable tumor regression in castration-resistant and patient-derived xenograft models, and exhibits good tolerability. JYZ3032 can be used in research related to metastatic castration-resistant prostate cancer and prostate cancer .
Cat. No.: HY-168555A
YJ1206 TFA is an orally active selective CDK12/CDK13 PROTAC degrader. YJ1206 TFA induces DNA damage and genomic instability, activates the AKT pathway, and triggers apoptosis. YJ1206 TFA reduces tumor cell viability, inhibits tumor growth, and attenuates tumor cell dissemination. YJ1206 TFA is applicable to research related to prostate cancer and high-grade serous tubo-ovarian cancer .
Cat. No.: HY-183667
CAS No.: 1332390-06-3
Target:
Research Areas:
JNJ-pan-AR is an orally active androgen receptor (AR) inhibitor with an IC50 of 19 nM and a Ki of 8.4 nM against human wild-type AR. JNJ-pan-AR abolishes androgen-induced KLK2 and KLK3 mRNA expression and reduces androgen-dependent colony formation in prostate cancer cells. JNJ-pan-AR blocks AR nuclear translocation, inhibits PSA protein expression, and represses the growth of AR-dependent tumor cells and ARF877L-driven tumor xenografts. JNJ-pan-AR blocks transactivation and signaling of wild-type AR and various mutant AR variants. JNJ-pan-AR is applicable for research on castration-resistant prostate cancer .
Cat. No.: HY-19337S
CAS No.: 2484757-41-5
Synonyms: BAY 1896953-d3; ORM-15341-d3
Cat. No.: HY-19337S1
Synonyms: BAY 1896953-d6; ORM-15341-d6
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
